NEW YORK (GenomeWeb) – Craig-Hallum Capital Group today upgraded shares of Cepheid to a Buy rating, based on recent deals with Quest Diagnostics and Laboratory Corporation of America and an expansion of its product portfolio.

Analyst Bill Bonello upgraded the shares from a previous Hold rating and raised the price target to $75 per share from $52.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.